PROKIDNEY CORP.
PROK · XNASCIK 1850270fmd_1DVPZSMGZT47VD6SZRJ4RCQHQRManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 23 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 0 | 0 | 1 |
| Realized investment gains (losses) | – | – | 0 | 6 | 7 | 3 |
| Research and development | 21 | 46 | 82 | 107 | 128 | 114 |
| Total operating expenses | 27 | 55 | 153 | 152 | 184 | 166 |
| Operating income | (27) | (55) | (153) | (152) | (184) | (165) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | (27) | (55) | (147) | (129) | (164) | (151) |
| Income tax expense | (0) | 0 | 1 | 6 | (1) | 0 |
| Net income from continuing operations | (27) | (55) | (148) | (135) | (163) | (152) |
| Net income | (27) | (55) | (148) | (35) | (61) | (69) |